key: cord-0985700-mtz96r0f
authors: Rafiee, Faranak; Keshavarz, Pedram; Katal, Sanaz; Assadi, Majid; Nejati, Seyed Faraz; Sadabad, Faranak Ebrahimian; Gholamrezanezhad, Ali
title: Coronavirus Disease 2019 (COVID-19) in Molecular Imaging: A systematic review of incidental detection of SARS-CoV-2 pneumonia on PET studies
date: 2020-10-28
journal: Semin Nucl Med
DOI: 10.1053/j.semnuclmed.2020.10.002
sha: c1f18e6d66b1b56f21b703fc47074f8da7913f7b
doc_id: 985700
cord_uid: mtz96r0f

PURPOSE: There have been several reports of the incidental detection of SARS-CoV-2 pneumonia on Positron Emission Tomography/Computed Tomography (PET/CT) studies, which represent the potential role of molecular imaging in detection and management of coronavirus disease 2019 (COVID-19). Here, we systematically review the value of PET/CT in this setting. MATERIALS AND METHODS: We conducted a systematic search on June 23, 2020, for PET studies with findings suggestive of COVID-19. Web of Science, PubMed, Scopus, EMBASE, and Google Scholar databases were used. Patients with at least one PET/CT imaging evaluation were included in the study. RESULTS: Fifty-two patients in 30 publications with a mean age of 60 ± 12.74 (age range; 27-87) were included in this study, of which 28(53.8%) were male, and 19(36.5%) were female. PET/CT was performed with (18)F-FDG for 49(94.2%), (18)F-choline for 2(3.8%), and (68)Ga-PSMA for 1 (1.9%) patients. The mean SUV max of pulmonary lesions with (18)F-FDG uptake was 4.9 ± 2.3. Moreover, 39(75%) cases had an underlying malignancy, including 18 different type of primary cancers and 6(11.5%) patients with metastatic disease. The most common pulmonary findings in PET/CT were bilateral hypermetabolic GGOs 39(75%), consolidation 18(34.6%), and interlobular thickening 4(7.6%). In addition, mediastinal 14(27%) and hilar 10(19.2%) lymph node involvement with increased metabolic activity were frequently identified. CONCLUSION: Early diagnosis of SARS-CoV-2 pneumonia is not only crucial for both appropriate patient management but also helps to ensure appropriate post-exposure precautions are implemented for the department and hospital staff and those who have been in contact with the patient.

The novel Coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 coronavirus), first emerged in China, and then spread to the other regions worldwide (1) . Currently, almost all countries have been seriously affected by the global pandemic, with profound impacts on their healthcare and socioeconomic systems. As of July 23, 2020, a total of 15 million COVID-19 cases with around 630.000 deaths have been confirmed worldwide (2) . COVID-19 typically presents with fever and lower respiratory symptoms, and the majority of infected patients display bilateral multifocal pulmonary lesions in chest imaging. No definitive therapy for the SARS-CoV-2 infection is available yet. Hence, early diagnosis, early isolation, and supportive management continue to be the crucial strategies to combat the present crisis (3) . Viral RNA nucleic acid testing (RT-PCR) is currently considered as the gold standard diagnosis; however, the test suffers insufficient sensitivity, particularly in the early time course of the disease (4, 5) . Therefore, chest imaging, specifically high-resolution CT, has been purposed as a supportive tool in the detection and management of SARS-CoV-2 pneumonia.

Recently, numerous publications have described the major imaging features of COVID-19.

Multifocal ground-glass opacities (GGOs) with a peripheral distribution and later superimposition of consolidation are amongst the most frequent reported characteristics (6) (7) (8) .

However, the mentioned findings are not specific for COVID-19, and several other lung pathologies might also mimic similar CT manifestations.

Moreover, despite some uncertainties due to the lack of enough data in this field, there might be a potential role for other imaging tools (e.g. Positron emission tomography/computed tomography or PET/CT) in the detection and management of COVID-19 (9) . Although 18 Ffluorodeoxyglucose ( 18 F-FDG) PET/CT is not usually applied in the diagnosis of acute pneumonia, its clinical value in the pulmonary inflammatory/infectious conditions has already been explored (10) . Besides, 18 F-FDG PET can assess the severity of disease, monitor disease progression, and evaluate the post-therapy response (11) . More importantly, the whole-body PET/CT imaging offers a unique chance to evaluate the possible extrapulmonary manifestations of COVID-19.

Over the last few months, several case reports with incidental detection of COVID-19 on PET/CT have been issued worldwide (12, 13) . However, a comprehensive study is still lacking in this regard. Hence, we conducted the present study to comprehensively review the available publications on PET/CT findings in COVID-19, which might guide us to a better understanding of the disease pathology, its long-term complications, and developing novel therapies. Indeed, the potential added value of FDG PET/CT in depicting the underlying pathophysiological inflammatory process might offer a great chance to fight against the ongoing COVID-19

Pandemic.

We conducted a systematic search for available published articles describing PET findings in COVID-19 patients. The search was performed on June 23, 2020, using Web of Science, PubMed, Scopus, EMBASE, and Google Scholar databases. The following search keywords were used: "COVID-19," "coronavirus," "coronavirus and infection", "SARS-CoV-19", "2019-CoV-19", "radiolog*","Tomography, X-ray, Computed", "Positron-Emission Tomography", "PET/CT*", and "FDG-PET". The full list of keywords which were used in the databases is provided as appendix 1. The study flow diagram is also presented in Figure 1 .

Patients with confirmed COVID-19 infection by RT-PCR test using nasopharyngeal swabs; with at least one PET/CT imaging evaluation were included in the study. Duplicate studies, conference abstracts, irrelevant reports, and studies in any language except English were excluded.

Regarding the quality assessment, two independent reviewers assessed the risk of bias of the included studies using the National Institutes of Health (NIH) quality assessment tool for case series/reports (14), and cohort studies using the modified version of Newcastle-Ottawa Quality Scale (NOS) (15)(Suppl. Tables 1,2). Two blinded reviewers extracted data and then proceeded to cross-check the results. The third reviewer resolved disagreements via consensus. The following data were extracted: First author's name, study region, study type, patient's age, gender, type of cancer, pulmonary PET/CT imaging findings, extra-pulmonary PET/CT imaging findings, maximum standardized uptake values (SUVmax) in PET/CT imaging, and outcome.

Moreover, we reported one patient in our center (Fig. 2 ) and a series of PET/CT images from three included studies (16) (17) (18) via formal permissions obtained from their publishers. (Fig 3-5 )

After excluding the duplicate search results and full-text final review, 30 studies were included in the final review: 19 case reports, 3 case series, 2 cohort studies, and 6 letters to the editor and commentaries. According to NIH and NOS quality assessment tools, quality of included studies was predominantly fair (Supplementary tables 1 and 2). Fifty-two patients with a mean age of 60 ± 12.74 (age range; 27-87, age IQR; 55-67 years old) were included in this study, of which 28(53.8%) were male, and 19(36.5%) were female. In 5(9.6%) patients, the gender was not reported (Table 1) . PET/CT scan was performed with 18 F-FDG for 49(94.2%), 18F-choline for 2(3.8%), and 68 Gallium-prostate-specific membrane antigen ( 68 Ga-PSMA) for 1(1.9%) patients.

Additionally, one patient (no. 2) had both 18 F-FDG PET/CT and PET/MR. The mean SUV max of pulmonary lesions with 18 F-FDG uptake was 4.9 ± 2.3, with a range of 2.2 to 18. Besides, mildly increased activity of pulmonary lesions was observed with 18 F-choline and 68 Ga-PSMA uptake (SUVmax of 3.8 and 3.2, retrospectively). With regards to the patient's chronic disease, 39(75%) cases had underlying cancer, including 18 different types of cancer, presented in Table   2 . Besides, 6(11.5%) patients had metastases to other organs such as bone (n=2), lung (n=2), liver (n=1), and lymph nodes (n=1).

The most common pulmonary PET/CT findings were hypermetabolic bilateral GGOs 39(75%), followed by consolidation 18(34.6%), and interlobular thickening 4(7.6%). Besides, mediastinal 14(27%), and hilar 10(19.2%) lymph node involvement with high metabolic activity was frequently seen. All of these findings are reviewed in Table 3 .

Four patients (no. 3, no. 8, no. 21, and no. 51) were discharged from the hospital; Patient no. 3 was a known case of Hodgkin's lymphoma, with a history of diabetes and morbid obesity, who was referred for staging PET in an outpatient facility. She did not have any travel history or contact with COVID-19 cases. The PET/CT showed stage II right pelvic adenopathy with only mild 18 F-FDG activity (SUVmax 2.9). Besides, the doctors incidentally found some multifocal bilateral peripheral lung opacities with moderate 18 F-FDG activity (SUVmax 4.5) in the left lower lobe. Two days later, she got a runny nose, coughing and fever (38 °C). After one-week hospitalization, she discharged without any symptoms, but her pelvic radiation was postponed due to the restrictions carried out during the COVID-19 pandemic. Patient no. 51, again from Wuhan, presented with fever, fatigue and dry cough for 5 days. His previous CT suggested hilar malignancy, and therefore 18 F-FDG was done for better assessment, which showed an FDG-avid mass with a SUVmax of 4.9 in the right lung and increased accumulation of FDG in the right paratracheal and right hilar lymph nodes, as well as bone marrow (Fig.3) . First nasopharyngeal swab tests were negative for COVID-19 infection, or other common respiratory viral infections. However, the second RT-PCR test turned positive for COVID-19 infection, and, the patient recovered and discharged from the hospital after 10 days of admission.

In terms of COVID-related extrapulmonary PET/CT findings, only one patient (no 34) with anosmia was reported. She was a 27-year-old healthy woman with no respiratory problems, who was presented with persistent isolated anosmia for 6 weeks. PET/CT revealed hypometabolism in the left orbitofrontal cortex (SUVmax of 9.5 on the left side, in comparison with 10 on the right side). Though, FDG uptake in the left inferior temporal cortex was normal. (Fig.5 ) 18 F-choline PET/CT was performed for only two patients (no. 27 and no. 45). Patient no. 27 was a 59-year-old man with a history of recurrent prostate cancer. 18 F-choline PET/CT performed after radical prostatectomy for evaluation of disease spread. This patient had no respiratory symptoms or fever. Choline PET revealed bilateral subsegmental peripheral areas of GGOs in the lungs with an increased choline-PET uptake (SUV max range 3-4). No pleural effusion or mediastinal lymph node involvement was noted. In addition, bone metastases with no pelvic nodal involvement were detected. After 36 hours of choline PET examination, the patient got dizziness, fatigue, and respiratory failure, and thus was admitted in the hospital.

As COVID-19 continues throughout the world, a variety of imaging findings have been reported worldwide. Chest imaging (using CXR and CT) has been successfully applied as a practical supplement to RT-PCR testing for COVID-19 diagnosis. Moreover, in most literature, CT Furthermore, these patients are more prone to developing complications related to SARS-CoV-2 infection, with increased rates of hospital admissions and mortality, stressing the need for early detection and management of SARS-CoV-2 pneumonia in this high-risk population. The detection of incidental COVID-19 pneumonia in FDG PET/CT findings has been common in recent studies (16, 17, 23) . Yet, the reports are so limited and sparse, and a comprehensive review of these manifestations is still lacking. Here, we systematically reviewed PET-CT findings in the available published articles describing incidental SARS-CoV-2 pneumonia features. To the best of our knowledge, this is the first systematic review in this regard. We found bilateral GGOs, consolidation, and interlobular thickening as the most common CT features in COVID-19 PET imaging, consistent with previous radiologic reports (24, 25). Furthermore, these pulmonary lesions displayed increased FDG uptake, which is not unexpected, as acute pneumonia is characterized by hypermetabolism in PET imaging. Reported SUVs have ranged from 2.2 to 18, with a mean pulmonary lesions SUVmax of 4.9.

Sufficient evidence about the potential utility of FDG PET/CT in the diagnosis and management of infectious and inflammatory diseases already exists (26) . Increased glycolytic activity in the inflammatory cells enables FDG PET to identify active inflammation sites throughout the body. Besides, the acute infectious process in COVID-19 could also be mapped via PET imaging in patients with immunocompromising underlying diseases, such as cancers.

Additionally noted, even in the absence of anatomically nodal enlargement, increased tracer uptake was frequently seen in the mediastinal and hilar lymph nodes. This suggests that COVID-19 causes lymphadenitis presenting with increases FDG uptake, which contradicts previous radiologic studies about rare nodal involvement in COVID-19 pneumonia (27, 28) .

Moreover, the extrapulmonary findings of COVID-19 have been reported recently in many literatures, causing complications in the brain, gastrointestinal tract, heart and kidneys (29, 30) .

In this era, a unique advantage of whole-body PET/CT over competing for imaging modalities is Overall, the potential value of PET imaging to better understand and characterize the disease, might help us improve our coping strategies during this ongoing pandemic. However, although contested by many the fact that PET can be a non-invasive beneficial imaging tool in the early detection and monitoring the COVDI-19 pneumonia in high-risk patients, we believe that PET should not be recommended in the diagnostic work-up of COVID-19 and other infectious types of pneumonia, as poses the risk of the disease spreading in nuclear medicine units and other imaging modalities are available that can provide sufficient clinical and diagnostic information (34) . Thus, more investigations with modified protocols are needed in future, to fully explore the possible clinical indications of molecular imaging for characterizing the disease severity and its prognosis (35) . Incidental detection of different abnormalities in nuclear medicine studies has been widely discussed in the literature. Accordingly, we strongly recommend the evaluation of PET images for previously unsuspected pathologies in daily practice, as this may eventually lead to uncovering of crucial pathologies that significantly change the patient management and prognosis. This is particularly important with the evolving diseases of the 21 st century(21, 22, 36) .

This systematic review gains a deep insight over the diagnostic value of detecting COVID-19 on PET imaging performed for other clinical indications. As patients undergoing PET imaging usually suffer from immunocompromising underlying diseases, such as cancers, early detection of potentially life-threatening and devastating pneumonia in these patients is of paramount importance to minimize the disease complications and limit the progression. This does not only help to uncover clinically unsuspected COVID-19 in this sensitive population, but also helps to ensure appropriate post-exposure precautions are implemented for the department and hospital staff and those who have been in contact with the patient.

The novel Coronavirus disease 

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Coronavirus disease (COVID-2019) situation reports

Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients

Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases

A Systematic Review of Pregnancy and the Possibility of Vertical Transmission

Chest-CT findings of COVID-19 in patients with pre-existing malignancies; a pictorial review

Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review

Long-term Pulmonary Consequences of Coronavirus Disease 2019 (COVID-19): What We Know and What to Expect

COVID-19: A Multimodality Review of Radiologic Techniques, Clinical Utility, and Imaging Features

Role of fluorine 18 fluorodeoxyglucose positron emission tomography-computed tomography in focal and generalized infectious and inflammatory disorders

Molecular Imaging of Pulmonary Inflammation and Infection

Incidental COVID-19 on PET/CT imaging

A case of coronavirus infection incidentally found on FDG PET/CT scan. Clin Nucl Med. 2020. 14. aBIw NHL. Study quality assessment tools

Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle-Ottawa scale and the RTI item bank

FDG PET/CT of COVID-19

Activated macrophages are the main inflammatory cell in COVID-19 interstitial pneumonia infiltrates. Is it possible to show their metabolic activity and thus the grade of inflammatory burden with 18F-Fluorocholine PET/CT? Med Hypotheses

18FDG PET/CT scan reveals hypoactive orbitofrontal cortex in anosmia of COVID-19. Academic Radiol. 2020. 19

An update on the unparalleled impact of FDG-PET imaging on the day-to-day practice of medicine with emphasis on management of infectious/inflammatory disorders. Eur J Nucl Med Mol Imaging. 2020. 21. Gholamrezanezhad A, Guermazi A, Salavati A, et al. PET-Computed Tomography and PET-MR Imaging and Their Applications in the Twenty-First Century

Coronavirus disease 2019 (COVID-19) pneumonia incidentally detected on coronary CT angiogram: a do-not-miss diagnosis

Radiology perspective of coronavirus disease 2019 (COVID-19): lessons from severe acute respiratory syndrome and Middle East respiratory syndrome

Early CT features and temporal lung changes in COVID-19 pneumonia in Wuhan, China

Diagnostic performance of 18F-FDG PET/CT in infectious and inflammatory diseases according to published meta-analyses

Early clinical and CT manifestations of coronavirus disease 2019 (COVID-19) pneumonia

Chest CT findings in patients with coronavirus disease 2019 and its relationship with clinical features

Neuroimaging findings in COVID-19 and other coronavirus infections: a systematic review in 116 patients. Neuroradiology. 2020. 30

Modeling [18 F]-FDG lymphoid tissue kinetics to characterize nonhuman primate immune response to Middle East respiratory syndromecoronavirus aerosol challenge

Unknown SARS-CoV-2 pneumonia detected by PET/CT in patients with cancer

The potential added value of FDG PET/CT for COVID-19 pneumonia

18F-FDG PET/CT and COVID-19

PET imaging of COVID-19: the target and the number

An important but easily forgettable review: extracardiac activity in myocardial perfusion scans

Asymptomatic COVID-19 positive patient suspected on FDG-PET/CT

PET/MR and PET/CT in a severe COVID-19 patient

COVID-19 Incidentally Detected on PET/CT During Work-up for Locally Advanced Head and Neck Cancer

Positron Emission Tomography for Detecting COVID-19 in Asymptomatic Left Ventricular Assist Device Recipients

18F-FDG PET/CT and serial chest CT findings in a COVID-19 patient with dynamic clinical characteristics in different period

18 F-FDG PET/CT findings of COVID-19: a series of four highly suspected cases

Nuclear medicine operations in the times of COVID-19: strategies, precautions, and experiences

Incidental findings suggestive of COVID-19 in asymptomatic patients undergoing nuclear medicine procedures in a high-prevalence region

Nursing home physician with normal chest X-ray and probable COVID-19 based on 18F-FDG PET/CT imaging

18F-fluorodeoxyglucose uptake in patient with asymptomatic severe acute respiratory syndrome coronavirus 2 (coronavirus disease 2019) referred to positron emission tomography/computed tomography for NSCLC restaging

Case report: incidental findings of COVID-19 infection on positron emission tomography/computed tomography for staging of a giant gastric gastrointestinal stromal tumour

FDG PET/CT in Diagnosing

Infection in a Cancer Patient With Exposure History But Minimal Symptoms

COVID-19 pneumonia: increased choline uptake with 18F-choline PET/CT

FDG-PET/CT findings highly suspicious for COVID-19 in an Italian case series of asymptomatic patients

18F]-FDG PET/CT for suspected lymphoma relapse in a patient with concomitant pneumococcal pneumonia during COVID-19 outbreak: unexpected SARS-Cov-2 co-infection despite double RT-PCR negativity

FDG-PET/CT and clinical findings before and during early Covid-19 onset in a patient affected by vascular tumour

FDG PET/CT in a Patient With Mantle Cell Lymphoma and COVID-19: Typical Findings

18F-FDG PET/CT in asymptomatic patients with COVID-19: The submerged iceberg surfaces

FDG PET/CT Findings in an Asymptomatic Case of Confirmed COVID-19

Laboratory-Proven Asymptomatic SARS-CoV-2 (COVID-19) Infection on 18F-FDG PET/CT